PharmaEssentia: Revenue doubled YoY as operating income rose 168%
קריאה של פחות מדקה
Q3 revenue reached NT$7.76B, up 100% YoY, while operating income rose 168% and net income increased 98%. ROPEG approvals expanded across ET markets, and PMF Phase 3 enrollment completed with a positive DSMB recommendation to continue.
Original document: PharmaEssentia Corp. [6446] Slides Release — Nov. 11 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr